- Home
- ORGO vs PHAR Comparison
ORGO vs PHAR Comparison
Compare ORGO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- PHAR
- Stock Information
- Founded
- ORGO 1985
- PHAR 1988
- Country
- ORGO United States
- PHAR Netherlands
- Employees
- ORGO N/A
- PHAR N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- PHAR Health Care
- Exchange
- ORGO Nasdaq
- PHAR Nasdaq
- Market Cap
- ORGO 533.9M
- PHAR 587.5M
- IPO Year
- ORGO N/A
- PHAR N/A
- Fundamental
- Price
- ORGO $5.34
- PHAR $10.01
- Analyst Decision
- ORGO Buy
- PHAR Strong Buy
- Analyst Count
- ORGO 2
- PHAR 3
- Target Price
- ORGO $5.50
- PHAR $30.00
- AVG Volume (30 Days)
- ORGO 1.7M
- PHAR 3.0K
- Earning Date
- ORGO 05-08-2025
- PHAR 05-08-2025
- Dividend Yield
- ORGO N/A
- PHAR N/A
- EPS Growth
- ORGO N/A
- PHAR N/A
- EPS
- ORGO N/A
- PHAR N/A
- Revenue
- ORGO $482,043,000.00
- PHAR $23,805,200,000.00
- Revenue This Year
- ORGO $3.31
- PHAR $12.39
- Revenue Next Year
- ORGO $12.50
- PHAR $9.84
- P/E Ratio
- ORGO N/A
- PHAR N/A
- Revenue Growth
- ORGO 11.29
- PHAR 9113.93
- 52 Week Low
- ORGO $2.17
- PHAR $6.65
- 52 Week High
- ORGO $6.71
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- ORGO 67.16
- PHAR 71.58
- Support Level
- ORGO $5.14
- PHAR $8.60
- Resistance Level
- ORGO $5.42
- PHAR $9.40
- Average True Range (ATR)
- ORGO 0.28
- PHAR 0.34
- MACD
- ORGO 0.09
- PHAR 0.15
- Stochastic Oscillator
- ORGO 85.09
- PHAR 87.89
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.